On July 12, 2024, coinciding with the 10th anniversary of the Chinese Academy of Medical Sciences Institute of Systems Medicine/Suzhou Institute of Systems Medicine (referred to as “Suzhou Systems Institute”), the 2024 Systems Medicine Forum was successfully held in Suzhou.

On July 12, Baheal Pharma (301015.SZ) announced the successful acquisition of Shanghai Baheal Pharma Co., Ltd. ("Baheal Pharma Co."), following the completion of business registration changes and handover procedures. Through this acquisition, Baheal Pharma now directly holds 60.199% of Baheal Pharma Co.'s shares, making it the controlling shareholder. As a result, Baheal Pharma Co.'s financial performance and status will be consolidated into Baheal Pharma's financial statements.

Recently, the 2024 Misi Conference (China's Pharmaceutical and Health Industry Synergy Conference), organized by the authoritative pharmaceutical information service platform Menet, opened in Huzhou. At the event, the highly anticipated "2023 Top 100 Chinese Pharmaceutical Companies" list was officially unveiled. Shanghai Huanghai Pharmaceutical Co., Ltd. (henceforth "Shanghai Huanghai Pharmaceutical"), a subsidiary of Shanghai Baheal Pharmaceutical Co., Ltd. (henceforth "Baheal Pharma"), was prominently featured on the "2023 Top 100 Traditional Chinese Medicine Companies" list, thanks to its strong capabilities in modern traditional Chinese medicine research and production.

Baheal Pharmaceutical Co. Ltd., with its headquarters in Shanghai, celebrates as its subsidiary, Qingdao Baheal Pharmaceutical Co. Ltd., has been graced with a flawless report from the US Food and Drug Administration (FDA). The agency's recent inspection concluded with a commendable 'No Action Indicated' (NAI) classification and without a single Form 483 observation - a testament to the company's strict adherence to the Current Good Manufacturing Practice (cGMP) guidelines. This clean bill of health is not the first for Qingdao Baheal Pharmaceutical, which previously achieved a 'zero-deficiency' rating in 2016, solidifying its stellar standing with the FDA.

On May 9, 2024, Baheal Pharma (301015.SZ) introduced a new product under its imported calcium brand, D·Cal: D·Cal Peachy Sachets®. This product innovation focuses on women's bone health needs, providing consumers with a fresh calcium supplementation experience.